Related Experiment Video
Updated: Jul 9, 2026
Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
Published on: May 2, 2022
Why precision oncology works: lessons from gastrointestinal stromal tumours
Si Ying Adelina Ho1, Alwyn Hong Sheng Tok2, Hui Qi Megan Kimberly Han2
1Ministry of Health Holdings, Singapore 139691, Singapore.
Abstract:
Gastrointestinal stromal tumours (GISTs) are the clearest solid-tumour model of precision oncology because diagnosis, prognosis, and treatment are strongly shaped by molecular genotype. The discovery of activating mutations in KIT proto-oncogene receptor tyrosine kinase (KIT) and platelet-derived growth factor receptor alpha (PDGFRA) transformed management by enabling genotype-directed use of tyrosine kinase inhibitors (TKIs) across localized and advanced disease. This review summarizes how molecular classification informs contemporary GIST care, from diagnostic work-up and risk stratification to neoadjuvant, adjuvant, and metastatic treatment planning. KIT exon 11 mutations generally predict sensitivity to standard-dose imatinib, whereas KIT exon 9 tumours may benefit from dose escalation. PDGFRA D842V confers primary resistance to imatinib but sensitivity to avapritinib, illustrating the clinical value of mutation-specific therapy. We also review KIT/PDGFRA-wild-type GISTs, including succinate dehydrogenase (SDH)-deficient, neurofibromin 1 (NF1)-associated, B-Raf proto-oncogene (BRAF)-mutant, and neurotrophic tyrosine receptor kinase (NTRK)-rearranged subtypes, where extended molecular testing is increasingly important. Surgery remains central in localized disease, but operative timing, extent of resection, and use of neoadjuvant therapy should be individualized according to tumour site, rupture risk, technical feasibility, and genotype. In advanced disease, sequential use of imatinib, sunitinib, regorafenib, ripretinib, and selected mutation-specific agents reflects evolving resistance biology and the need for ongoing molecular interpretation. Emerging tools such as broader genomic profiling and liquid biopsy may further refine treatment selection. GIST therefore demonstrates that precision oncology is most effective when molecular diagnostics, surgery, systemic therapy, and multidisciplinary decision-making are integrated across the full disease course.
Insights
Gastrointestinal stromal tumours (GISTs) management is guided by molecular genotype, enabling precision oncology. Understanding specific mutations in KIT and PDGFRA drives targeted tyrosine kinase inhibitor (TKI) therapy for improved patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Precision Medicine
Background:
- Gastrointestinal stromal tumours (GISTs) are a prime model for precision oncology due to genotype-driven diagnosis, prognosis, and treatment.
- Activating mutations in KIT proto-oncogene receptor tyrosine kinase (KIT) and platelet-derived growth factor receptor alpha (PDGFRA) have revolutionized GIST management with genotype-directed tyrosine kinase inhibitors (TKIs).
Purpose of the Study:
- To review how molecular classification of GISTs informs contemporary care, including diagnosis, risk stratification, and treatment planning for localized and advanced disease.
- To highlight the importance of mutation-specific therapies and the evolving landscape of KIT/PDGFRA-wild-type GISTs.
- To emphasize the integration of molecular diagnostics, surgery, and systemic therapy in precision oncology for GIST.
Main Methods:
- Literature review summarizing current understanding of GIST molecular classification and its clinical implications.
- Analysis of genotype-directed treatment strategies for various GIST subtypes, including KIT/PDGFRA mutations and wild-type cases.
- Discussion of the role of surgery, neoadjuvant therapy, and sequential TKIs in managing localized and advanced GIST.
Main Results:
- KIT exon 11 mutations typically respond to standard imatinib, while KIT exon 9 may require dose escalation.
- PDGFRA D842V mutations confer imatinib resistance but sensitivity to avapritinib, underscoring mutation-specific treatment value.
- Management of KIT/PDGFRA-wild-type GISTs, including SDH-deficient and NF1-associated subtypes, requires extended molecular testing.
Conclusions:
- Molecular classification is crucial for optimizing GIST diagnosis, risk stratification, and treatment selection.
- Personalized therapy, considering specific mutations and resistance patterns, is key to improving outcomes in advanced GIST.
- Integrated multidisciplinary decision-making, incorporating molecular diagnostics and tailored systemic therapy, is essential for effective precision oncology in GIST.
Related Concept Videos
02:56Treatment Resistant Cancers
02:56Treatment Resistent Cancers